Research Topics
| Lisa A HammondSummaryAffiliation: Cancer Therapy and Research Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pharmacokinetic evaluation of gefitinib when administered with chemotherapyLisa A Hammond
Institute for Drug Development, Cancer Therapy Research Center, San Antonio, TX, USA
Clin Lung Cancer 5:S18-21. 2003..The addition of gefitinib to these chemotherapy regimens was generally well tolerated, and there was no apparent increase in higher-grade toxicity. Additional trials are evaluating gefitinib treatment in combination with chemotherapy...- Positron emission tomography (PET): expanding the horizons of oncology drug developmentLisa A Hammond
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
Invest New Drugs 21:309-40. 2003..The progress to date and the challenges of incorporating PET technology into oncology drug development from the preclinical to clinical setting are reviewed in this article... - Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumorsAmita Patnaik
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
Clin Cancer Res 12:7406-13. 2006.... - Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
J Clin Oncol 24:552-62. 2006..Additional studies are needed to define appropriate dosing for renally impaired patients receiving higher dose pemetrexed with vitamin supplementation... 
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic studyJordi Rodon
Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229, USA
Cancer Chemother Pharmacol 62:911-9. 2008..This provided the rationale for the three-times weekly treatment explored in this protocol...- A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignanciesEric K Rowinsky
Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas, USA
Clin Cancer Res 13:532-9. 2007..The study also sought to detect major pharmacokinetic drug-drug interactions between these agents and preliminary evidence of antitumor activity in patients with advanced solid malignancies... - A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor propertiesSamira Syed
Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas 78229, USA
Clin Cancer Res 10:6512-21. 2004.... - Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesQuincy Siu-Chung Chu
Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
Clin Cancer Res 10:4913-21. 2004.... - A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignanciesBahram Forouzesh
Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
Clin Cancer Res 9:5540-9. 2003..The characteristics of the myelosuppressive effects of ILX-295501, the paucity of severe nonhematological toxicities, and preliminary antitumor activity warrant disease-directed evaluations of ILX-295501... - A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignanciesAmita Patnaik
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
Clin Cancer Res 9:4761-71. 2003..The study also sought to identify drug-drug pharmacokinetic interactions, evaluate effects on protein farnesylation, and seek preliminary evidence for clinical activity... - A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignanciesMitchell A Garrison
Brooke Army Medical Center, San Antonio, Texas 78229, USA
Clin Cancer Res 9:2527-37. 2003..The MTD was defined for both minimally pretreated (MP) and heavily pretreated (HP) patients as the highest dose level at which the incidence of dose-limiting toxicity does not exceed 20%... - Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumorsAlain C Mita
Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio 78229, USA
Clin Cancer Res 12:5207-15. 2006..v. infusion weekly for 3 weeks every 4 weeks... - A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanomaMonica M Mita
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
Cancer Chemother Pharmacol 59:165-74. 2007.... - Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumorsAlejandro D Ricart
Institute for Drug Development, Cancer Therapy and Research Center, and Department of Pharmacology, University of Texas Health Science Center at San Antonio 78229, USA
Clin Cancer Res 11:8728-36. 2005..Major toxicologic and pharmacologic differences between the two sequences of drug administration were also assessed... - ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomasJohann S de Bono
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
Clin Cancer Res 10:7555-65. 2004.... - A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignanciesLillian L Siu
Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
Clin Cancer Res 8:2157-66. 2002..Pharmacodynamic assessment of tumoral tissues in 1 study patient demonstrated changes in the levels of polyamines and their biosynthetic enzymes consistent with SAMDC inhibition... - Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative studyAnthony W Tolcher
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
J Clin Oncol 21:211-22. 2003..v.) once every 3 weeks and to seek evidence of antitumor activity... - Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancerAnthony W Tolcher
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
J Clin Oncol 24:2052-8. 2006.... - Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patientsShazli N Malik
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
Clin Cancer Res 9:2478-86. 2003..On the basis of these findings and the relatively simple and reliable method to measure p27 expression, this biomarker appears to be the most promising and is being evaluated in Phase II studies as a predictor of clinical outcome... - A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancerAnthony W Tolcher
Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas 78229, USA
Clin Cancer Res 10:5048-57. 2004.... - Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect studyEmiliano Calvo
Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
Clin Cancer Res 10:7112-20. 2004..Its tolerability and the biological relevance of concentrations achieved at the maximal tolerated dose warrant consideration of disease-directed evaluations. This intermittent treatment schedule can be used without regard to meals... - A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitorDesiree Hao
Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
Clin Cancer Res 9:2465-71. 2003..The purpose of this study was to assess the feasibility and characterize the pharmacokinetics of squalamine administered as a continuous i.v. infusion daily for 5 days every 3 weeks... - A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignanciesAmita Patnaik
Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, Texas 78229, USA
Clin Cancer Res 8:2142-8. 2002..Additional disease-directed clinical evaluations of AN-9 are necessary to establish the breadth of its antitumor activity and to assess its role as an effective differentiating agent... - A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignanciesEric K Rowinsky
Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, TX, USA
J Clin Oncol 21:148-57. 2003..The study also sought to determine the maximum-tolerated dose (MTD) of PEG-CPT, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity... - A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasmsLisa A Hammond
Cancer Therapy and Research Center, University of San Antonio Health Science Center at San Antonio, San Antonio, Texas, USA
Clin Cancer Res 10:1645-56. 2004..The characteristics of the myelosuppressive effects of BCNU/TEM, the paucity of severe nonhematological toxicities, and antitumor activity at tolerable doses warrant disease-directed evaluations on this schedule... - An image worth a thousand lives?Lisa A Hammond
ILEX Products, San Antonio, Texas 78229, USA
Nat Biotechnol 22:677-8. 2004 - Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesJohann S de Bono
Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 8122 Datapoint Drive, Suite 700, San Antonio, TX 78229, USA
J Clin Oncol 20:96-109. 2002..5 and 1.2 mg/m(2)/d for MP and HP patients, respectively. Broad disease-directed evaluations of troxacitabine on this schedule and possibly less frequent schedules are warranted... - Acute retinal toxicity from the novel anti-tumor agent, IrofulvenRobert F Melendez
Department of Ophthalmology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA
Doc Ophthalmol 108:249-51. 2004 - A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumorsScot Ebbinghaus
Arizona Cancer Center, University of Arizona, Tucson, USA
Clin Cancer Res 11:7807-16. 2005.... - HER-targeted tyrosine-kinase inhibitorsJose Baselga
Medical Oncology Service, Hospital General, Universitari Vall d Hebron, Pg Vall d Hebron 199 129, E 08035 Barcelona, Spain
Oncology 63:6-16. 2002..Early data show that they are generally well tolerated and have provided evidence of antitumor activity. HER-TK inhibitors are exciting agents that are likely to have a substantial impact on the way we treat patients with cancer... - Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf
Clinical Treatment Unit, The Ohio State University Comprehensive Cancer Center, 1248 James Cancer Hospital, 300 West 10th Avenue, Columbus, 43210, USA
Clin Cancer Res 12:3782-91. 2006..To determine the recommended starting doses and pharmacokinetics of irinotecan in cancer patients with impaired liver function treated on a weekly schedule... - A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancerRoy S Herbst
Department of Thoracic/Head and Neck Medical Oncology and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 9:4108-15. 2003.... - ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trialMalcolm Ranson
Christie Hospital and Royal Eye Hospital, Manchester, United Kingdom
J Clin Oncol 20:2240-50. 2002..To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors... - Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumorsCasey Cunningham
Tyler Cancer Center, Texas, USA
Clin Cancer Res 11:7825-33. 2005..4 mg/m(2). The favorable toxicity profile of tasidotin compared with other antitubulin agents, including other dolastatin analogues, and its novel mechanism of action support further disease-directed evaluation of this agent... - Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancerRoman Perez-Soler
Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY 10467, USA
J Clin Oncol 22:3238-47. 2004..This phase II study of erlotinib in patients with HER1/EGFR-expressing non-small-cell lung cancer previously treated with platinum-based chemotherapy evaluated tumor response, survival, and symptom improvement...